However, recent data suggests that adaptation mechanisms to KRAS inhibition are cell-type (epithelial vs. mesenchymal) dependent and that even similar cell types engage different compensatory mechanisms20, highlighting the need to find drug combinations that span a large fraction of KRASG12C lung cancers. This evidence concerns the gene KRAS and lung cancer.